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INTERLEUKIN-10 (IL-10) is a cytokine derived from CD4
+
T-helper type 2 (TH2) cells identified as a suppressor
of cytokines  from  T-helper type  1(TH1)  cells.  Inter-
leukin-12 (IL-12) is produced by B cells, macrophages
and dendritic cells, and primarily  regulates TH1 cell
differentiation, while suppressing  the  expansion of
TH2 cell clones. Interferon-g (IFN-g ) is a  product  of
TH1 cells  and  exerts  inhibitory  effects  on  TH2 cell
differentiation. These cytokines have been implicated
in the pathogenesis of asthma and allergies. In this
context, IL-12 and IFN-g production in asthma have
been found to be decreased, and this may reduce their
capacity to inhibit IgE synthesis and allergic inflam-
mation.  IL-10  is  a  potent  inhibitor  of  monocyte/
macrophage function, suppressing the production of
many pro-inflammatory cytokines. A relative under-
production  of  IL-10  from  alveolar  macrophages  of
atopic  asthmatics  has  been  reported.  Therapeutic
modulation  of  TH1/TH2 imbalance  in  asthma  and
allergy  by  mycobacterial  vaccine,  specific  immuno-
therapy  and  cytolineÐguanosine  dinucleotide  motif
may lead to increases in IL-12 and IFN-g production.
Stimulation  of  IL-10  production  by  antigen-specific
T-cells  during  immunotherapy  may  lead  to  anergy
through  inhibition  of  CD28-costimulatory  molecule
signalling by IL-10s anti-inflammatory effect on baso-
phils, mast cells and eosinophils.
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Introduction
The chronic airway inflammation of asthma is charac-
terised by  infiltration of  the airway wall by  diverse
effector cells, including T lymphocytes, eosinophils,
monocytes/macrophages,  mast  cells,  and  occasion-
ally,  neutrophils.1–3 The  airway  wall  undergoes
chronic  structural  changes  labelled  as  remodelling,
which  include  thickening  of  the  airway  smooth
muscle  due to hypertrophy and hyperplasia, myofi-
broblast  activation  with  increase  in  subepithelial
basement membrane collagen deposition, angiogene-
sis and increase in submucosal blood vessels and an
increase in goblet cell numbers in the airway epithe-
lium.4,5 The mobilisation, activation and trafficking of
effector  cells  to  the  airway  are  controlled  by  a
complex  cytokine  milieu  derived  from  activated
CD4+ THelper (TH) cells and also from other resident
airway  cells  including  airway  smooth  muscle  and
epithelial cells. THelper cells of  type  2  variety (TH2)
secrete  a  TH2 profile  of  cytokines,  after  cognate
stimulation of the na¨ õ ve T-cell by antigen presenting
cells,  such  as  the  dendritic  cell  and  the  alveolar
macrophage. TH2 cytokines include IL-4, IL-5, IL-9, IL-
10  and  IL-13.  These  cytokines  promote  various
elements of allergic inflammation including propaga-
tion  of  the TH2 phenotype,  isotype-switching  from
IgG1 to IgE synthesis, eosinophil mobilisation, matura-
tion and activation and mast cell activation.6 Chronic
airway structural changes too are variably influenced
by TH2 cytokines, and certain growth factors.
TH1 cells form a natural counterbalance to TH2 cells
driving  protective  cell-mediated  immunity,  and  are
induced  on  exposure  to  foreign  agents  including
protozoa, bacteria and viral particles. TH1 responses
are characterised by the induction of cell mediated
immune responses and the synthesis of IgG2a, while
TH2 responses  are  of  humoral-type,  inciting  the
production of IgE and IgG4 TH1 responses inhibit TH2
responses through the production of cytokines such
as IL-12 and IFN-g . There is evidence for a preferential
skewing to the expansion of the CD4+ TH2 lympho-
cyte  subset  in  allergic  processes,  while  CD4+ TH1
responses may be subdued and this is a likely crucial
forerunner to development of allergic asthma. In this
context, the TH1 cytokines, IL-12 and IFN-g , may be
considered  to  be  ‘anti-inflammatory’  in  that  they
inhibit  certain  responses  attributable  to  TH2 cell
activation,  while  the  TH2 cytokine,  IL-10,  under
certain circumstances, may inhibit pro-inflammatory
activation of certain cells. The  manipulation  of  the
immune  allergic  system  to  promote TH1 responses
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under  certain  circumstances,  of  IL-10,  which  can
prevent the establishment of allergy  and of various
manifestations of allergic inflammation.
In this review, the important roles of IFN-g , IL-10
and  IL-12  in  inducing  the  therapeutic  benefits  of
various immune therapies for allergy and asthma will
be examined first, followed by a systematic review of
these anti-inflammatory cytokines.
Immunological imbalance of TH1 & TH2
cells
The  vast  majority  of  asthmatics  have  an  atopic
background, in  whom the inflammatory process of
asthma  may  be  driven  following  sensitisation  and
exposure  to  common  aeroallergens  to  which  they
become sensitised to. Allergen-derived peptides are
usually  taken  up  by  specialised  cells  on  mucosal
surfaces  such  as  dendritic  cells,  and  subsequently
processed and presented to na¨ õ ve T-cells. The activa-
tion  of  na¨ õ ve T-cells  requires  direct  signalling  by  2
distinct pathways: firstly via the CD4+ T-cell receptor
through  the  antigen-presenting  cell  (APC)-bound
antigen to MHC-II complex and, secondly, via the co-
stimulatory  pathway  linked  by  the  B7  family  and
T-cell  bound CD28.7 T-cells  stimulated via the T-cell
receptor  (TCR)  in  the  absence  of  co-stimulatory
signalling  are  incapable  of  IL-2  secretion  and  sub-
sequent  activation  and  therefore  enter  an  anergic
state.8 CD28 itself  has 2 major ligands, B7.1 which
inhibits  TH2 cell  activation  and  development,  and
B7.2, which induces T-cell activation, and TH2 devel-
opment.  An  important  third  ligand,  CTLA4,  is
expressed  on  activated T  cells,  binds  CD28  with
enhanced avidity and acts as a negative regulator of
T-cell function by inhibiting TH2 differentiation.9,10 In
those who later develop an allergic response, na¨ õ ve
T  cells  differentiate  into  the  TH2 subtype.  This
differentiation  is  induced  by  cytokines  themselves,
and  may  be  secreted  by  antigen-stimulated T  cells
themselves, or by other cells that become activated
by  T  cell  cytokines.  IFN-g secreted  by  TH1 cells
activate macrophages and dendritic cells, and in turn
induces  them  to  produce  IL-12,  the  main  TH1-
inducing  cytokine. TH1 and TH2 cells  produce cyto-
kines that cross-regulate and antagonise each other’s
activity  and  development.  IL-4  can  inhibit  IL-12
production,  and TH2 cytokines  (IL-4,  –10  and  –13)
antagonise  the  macrophage-activating  properties  of
TH1 cytokines. IFN-g is involved in the TH1 inhibition
of the effects of TH2 cells, such as bronchial hyper-
esponsiveness,  eosinophilia  and  mucus  goblet  cell
hyperplasia.11,12
T-cell  profiles  in  the newborn demonstrate a TH2
bias suggesting that prenatal influences are involved
in T-cell priming.13 During the course of maturation of
the normal infant, however, increased TH1 expression
occurs and the TH2 imbalance is overcome.14 Delay or
failure  of  this  TH1 response  may  result  in  TH2
persistence and atopy or atopic disease, and in infants
destined to become atopic, circulating lymphocytes
have  impaired  production  of  IFN-g .15 Recently,  a
‘hygiene hypothesis’ has been put forward stating that
a diminished induction of TH1 responses is a potential
explanation  for  the  rising  prevalence  of  atopy  and
asthma.13,16 Cross-sectional  surveys  have  identified
inverse relationships between prior microbial expo-
sure and development of atopy.15,17 Further, respira-
tory allergy appears less frequently in those heavily
exposed  to  orofaecal  and  foodborne  microbes.16
Improved hygiene, early infection and antibiotic use,
and a westernised or semi-sterile diet may facilitate
atopy  by  influencing  exposure  to  commensals and
pathogens  that  stimulate  immune  cell  populations
such  as  gut-associated  lymphoid  tissue.18,19 Thus,
early environmental exposure may be a determinant
of  the  development  of  atopy  in  the  adult.20 The
identification  of  ways  to  prevent,  control  or  even
reverse  the  process  of  TH2 immunodeviation  has
become a focus for the development of new strategies
to control asthma and allergies.
Therapeutic TH1/TH2 modulation: roles of
IL-10, IL-12 and IFN-g
The  potential  therapeutic  roles  of  IL-10,  IL-12  and
IFN-g in allergies and asthma are well illustrated by
various  potential  treatments.  Specific  immunother-
apy (SIT) by administration of allergen extracts is a
treatment  aimed  at  the  induction  of  specific  unre-
sponsiveness,  or  anergy,  in  peripheral  T-cells  to
peptide epitopes. This  treatment has  been success-
fully  used  in  asthma  and  allergic  rhinitis  and  for
venom  allergy,21,22 but  is  usually  most  useful  in
subjects  allergic  to  single  allergens  such  as  grass
pollens, and in subjects with mild forms of allergic
diseases.23,24.  Peripheral  T-cells  following  SIT  are
characterised  by  reduced  IL-4  and  IL-5,  and
increased IFN-g production by CD4+ T cells25–27 and
by  attenuated  proliferative  responses  to  specific
allergens.28 This process is initiated by an autocrine
effect  of  IL-10  produced  by  antigen-specific
T-cells.29–31 IL-10  induces  anergy  by  inhibition  of
CD28-costimulatory molecule signaling,32,33 and also
by anti-inflammatory effects on basophils, mast cells
and eosinophils. There are reduced levels of IL-4 and
IL-5  and  increased  IFN-g production,  indicating  a
shift  of  the  T  cells  towards  an  increased  TH1
response at the expense of TH2 responses.25,26 After
successful grass pollen immunotherapy, there is also
an increase in IL-12 and IFN-g mRNA expression in
tissues.34,35
The potential benefit of the mycobacterial vaccine,
Bacille-Calmette-Guerin  (BCG)  (Mycobacterium
bovis) vaccination, in atopic diseases was suggested
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diminished incidence of atopy and allergic disease in
Japanese  schoolchildren,  indicating  a  role  for  early
mycobacterial exposure in  the subsequent develop-
ment  of  atopic  responsiveness.15 Mice  vaccinated
with BCG prior to allergen sensitisation had increased
IFN-g and decreased IL-4 and IL-5 expression along
with reduced levels of airway T-cells and eosinophilia
and bronchial reactivity.36,37 Local production of IFN-
g induced by the BCG vaccine was the major cytokine
involved  in  blocking  atopic  disease  in  the  lung.36
Mycobacterium vaccae is ubiquitously present in the
soil as a saprophyte and can evoke a strong produc-
tion of IFN-g . Suppression of TH2 activation has been
demonstrated  using  heat-killed  M.  vaccae in
mice.38–40
The  cytosine–guanosine  dinucleotide  repeat,
when present in a particular base context, is known
as  a  CpG  motif  and  is  an  important  prokaryotic
immunomodulatory effector whose role is probably
that of a warning or priming agent against bacterial
infection.41 This  motif  is  expressed  at  very  low
frequency in vertebrates, in a non-functional methyl-
ated  form,  and  hence  is  without  function.  CpG
vaccination directly induces antigen-presenting cells
and B-lymphocytes to release IL-12, IL-18 and TNFg
effectively,  suppressing  TH2 responses  by  inducing
the  TH1 phenotype.  These  CpG  oligodinucleotides
(ODN)  prevent  the  development  of  eosinophilic
airway  inflammation,  allergen-induced  elevation  of
serum  IgE  and  bronchial  hyper-responsiveness  in
murine asthma models,42 and can also reduce estab-
lished  inflammation.42–44 The  protective  effects  of
CpG-ODN appear to be due to an induction of IL-12
and  IFN-g .42,45 Other  mechanisms  may  also  be
involved.46
Specific cytokine profiles
Interleukin-10
Synthesis and release.
IL-10, previously known as cytokine synthesis inhib-
itor  factor  (CSIF),  was  originally  identified  as  a
product  of  murine T  helper  (TH2)  clones that sup-
pressed the production of cytokines by TH1 clones
responding  to  stimulation  of antigen.47 In  humans,
TH0, TH1, and TH2-like CD4+ T cell clones, cytotoxic
T-cells, activated monocytes and peripheral blood T
cells  including  CD4+ and  CD8+ T-cells  have  the
capacity to produce IL-10.48,49 An autocrine action of
IL-10 with increased production of IL-10 by antigen-
specific cells may be responsible for the induction of
anergy.31 Mast cells also have the capacity to produce
IL-10.  Constitutive  IL-10  secretion  occurs  in  the
healthy lung with the major source being the alveolar
macrophage; however, the circulating monocyte elab-
orates more IL-10 than the alveolar macrophage.50
Receptors and signalling pathways.
IL-10R  has  been  characterised  and  cloned  from  a
human  lymphoma  cell  line,51 and  is  expressed  in
several lymphoid and myeloid cells,52 and also on NK
cells.53 The IL-10R is made up of 2 subunits, which
belong to the same class of receptor family that also
contains  receptors  for  IFN-g .54 The  IL-10  receptor
a -chain (110kDa) mediates high-affinity ligand bind-
ing and signal transduction,51,55 while the b subunit
(40kDa) is required for signalling.56The functional IL-
10R  complex  is  a  tetramer  consisting  of  2  IL-10
a -chains  and  2  IL-10  b -chains. Activation  of  IL-10R
leads to the activation of JAK-STAT signalling pathway,
with activation of JAK-1 by the a chain and TYK2 by
the  b chain.  These  kinases  then  phosphorylate
specific tyrosine residues on the intracellular domain
of  the IL-10R  a chain. Once phosphorylated, these
tyrosine residues serve as temporary docking sites for
the  latent  transcription  factors  STAT1,  STAT3  and
STAT5.57,58 STAT3 is directly recruited to the IL-10Ra
and becomes phosphorylated by receptor-associated
JAK kinases. STAT1 is also activated in macrophages.
Upon  phosphorylation,  STAT1  and  STAT3  homo/
heterodimerise and translocate to the nucleus where
they bind with high affinity to STAT-binding elements
in  the promoters of various IL-10-responsive genes.
One of these genes, SOCS-3 (suppressor of cytokine
signalling-3) is a member of a newly identified family
of genes that inhibit JAK/STAT-dependent signalling.
The  ability  of  IL-10  to  inhibit  gene  expression  in
monocytes  is  associated  with  its  ability  to  rapidly
induce the synthesis of SOCS-3.
Effects.
IL-10 is a pleiotropic cytokine that can exert either
immunosuppressive or immunostimulatory effects on
a variety of cell types. IL-10 is a potent inhibitor of
monocyte/macrophage function, suppressing the pro-
duction of a number of pro-inflammatory cytokines,
including  TNF-a ,  IL-1b ,  IL-6,  MIP-1a and  IL-8,59–61
although the  release  of  MCP-1  is  increased.61 IL-10
inhibits monocyte MHC Class II, B7.1/B7.2 and CD23
expression  and  accessory  cell  function.  Accessory
signals mediated by B7 molecules through CD28 on
the surface of T-cells are essential for T-cell activation.
Expression of IL-10 by antigen-presenting cells may be
an established pathway for the induction of antigen-
specific  tolerance,  such  as  that  to  allergens.62 By
contrast, IL-10 up-regulates the monocyte expression
of IL-1ra, another antiinflammatory cytokine.63 IL-10
suppresses  the  synthesis  of  superoxide  anions  and
NO by activated monocytes/macrophages.64 An IL-10
antibody  enhances  the  release  of  cytokines  from
activated  monocytes,  suggesting  that  this  cytokine
may play an inhibitory role when the cell is stimu-
lated.60 IL-10  inhibits  the  stimulated  release  of
RANTES and IL-8 from human airway smooth muscle
cells in culture.65,66
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TH1 lymphocytes,47 and IL-4 and IL-5 production by
TH2 cells  by  interfering  with  B7-CD28-dependent
signals.67,68 IL-10  inhibits  the  proliferative  T  cell
response in  peripheral  blood  mononuclear  cells  to
various antigens, and the superantigen staphyloccocal
enterotoxin B. IL-10 selectively inhibits the anti-CD28
stimulated proliferation of purified CD45RO+ T cells.
There is a constitutive association of CD28 with the
IL-10 receptor, and IL-10 acts directly on the CD28
signalling  pathway  to  inhibit  CD28  tyrosine  phos-
phorylation  and  binding  to  phosphatidylinositol
3-kinase.69 IL-10 also inhibits eosinophil survival and
IgE synthesis induced by IFN-g . On the other hand, IL-
10  acts  on  B-cells  to  enhance  their  viability,  cell
proliferation,  immunoglobulin  secretion  with  the
isotype  switch  and  class  II  MHC  expression.  IL-10
decreases IL-4-induced IgE switch in peripheral blood
mononuclear cells, but potentiates IgE production in
B-cells that are already switched to produce IgE.70 IL-
10 is also a growth co-stimulator for thymocytes and
mast cells,71 as well as an enhancer of cytotoxic T cell
development.72 IL-10 increases Bcl-2 expression and
survival  of  primary  human  CD34+  progenitor  cells
committed to the myeloid lineage.73 IL-10 also acti-
vates the transcription of genes for mast-cell derived
proteases. IL-10 enhances the production of the tissue
inhibitor  of  metalloproteinases  of  monocytes  and
tissue macrophages while  decreasing metalloprotei-
nase biosynthesis.74
Role in allergy and asthma.
There  is  significantly  less  IL-10  mRNA  and  protein
expressed  in  alveolar  macrophages  of  asthmatic
subjects  compared  to  those  from  non-asthmatic
individuals.75,76 Triggering of CD23 molecule by anti-
CD23 monoclonal antibodies induces IL-10  produc-
tion by human monocytes.77 An IL-10 polymorphism
on the transcription initiation site could be responsi-
ble  for  reduced  IL-10  release.75 Another  polymor-
phism  upstream from  this site was associated with
elevated  total  serum  IgE.78 Inhaled  corticosteroid
therapy  restores  the  reduced  IL-10  release  from
macrophages of asthmatics76 and theophylline increa-
ses IL-10 secretion.79 On the other hand, other studies
indicate that there are increased number  of macro-
phages  and T-cells  expressing  IL-10  mRNA  in  bron-
choalveolar lavage fluid of patients with asthma.80
Studies regarding the role of IL-10 in allergic mouse
models have provided some conflicting results. Co-
instillation of IL-10 by the intranasal route significantly
inhibits the peritoneal and lung eosinophilia induced
by ovalbumin in immunised mice;81–83 however, IL-10
augmented  airway  responsiveness.  Concurrent
expression  of  IL-10  and  GM-CSF  in  the  airway
epithelium  led  to  a  suppression  of  GM-CSF-driven
ovalbumin-specific  eosinophilic  inflammation  with
decreased IL-4, IL-5 and TNFg expression. However, in
IL-10 gene knock-out mice, allergen-induced eosino-
philic  inflammation,  IL-5  production  and  airway
hyper-responsiveness were inhibited.84–86These stud-
ies  in  mice  indicate  that  IL-10  may  augment  or
decrease allergic inflammatory responses, but could
worsen airway responsiveness.
IL-10 is involved in the induction of specific anergy
in peripheral T cells during specific immunotherapy,
characterised by  suppressed  proliferative  and  cyto-
kine responses. IL-10 administration before allergen
exposure induces antigen-specific T cell tolerance.31
IL-10-derived regulatory CD4+ T cells producing IL-10
but not IL-2 and IL-4 suppresses antigen-specific T cell
response  in  vitro and  prevented  antigen-induced
murine  colitis.87 Administration  of  IL-10  to  normal
volunteers  induced  a  fall  in  circulating  CD2,  CD3,
CD4  and  CD8  lymphocytes  with  suppression  of
mitogen-induced T-cell proliferation and reductions in
TNF-a and  IL-1b production  from  whole  blood
stimulated with endotoxin ex-vivo.88
Interferon-g
Synthesis and release.
IFN-g was  originally  identified  as  a  product  of
mitogen-stimulated T lymphocytes that inhibited viral
replication in fibroblasts. The known sources of IFN-g
are CD4+ and CD8+ T-cells and NK cells.
Receptors and signalling.
The receptor is expressed on T-cells, B-cells,  mono-
cytes/macrophages, dendritic cells, granulocytes and
platelets. Epithelial and endothelial cells also express
these receptors. IFN-g receptor consists of an a -chain
(90kDa) which is the major ligand binding subunit,
and of a b chain (65kDa) which increases the affinity
of  the  a chain  for  its  ligand,  but  is  obligatory  for
transducing the IFN-g signal.89,90 Signalling  through
the  IFN-g receptor  is  mediated  through  JAK1  and
JAK2, which are constitutively associated with spe-
cific membrane proximal residues on the cytoplasmic
domain of the receptor.91,92 Activated JAKs phosphor-
ylate  a  specific  tyrosine  residue,  to  which  STAT-1
binds  through  its  SH2  domain.93 STAT-1  is  in  turn
phosphorylated by receptor-associated JAKs and hom-
odimerisation  of  2  STAT-1  proteins  form  a  protein
complex,  GAF  (gamma-activated  factor).94 STAT-1
homodimer translocates to the nucleus where it binds
to a consensus sequence leading to modulation of the
expression  of  many  genes. The  recently  identified
SOCS (suppressors of  cytokine signalling)  family  of
proteins inhibits IFN-g signalling through the preven-
tion of JAK kinase activation.95
Effects.
IFN-g has  extensive  and  diverse  immunoregulatory
effects on various cells. It is produced by TH1-cells and
exerts  an  inhibitory  effect  on  TH2-cells.96 IFN-g
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the  mouse.97 However,  IFN-g may  also  have proin-
flammatory effects and may activate airway epithelial
cells  to  release  cytokines  and  express  adhesion
molecules.98 IFN-g has  an amplifying  effect  on  the
release of TNF-a from alveolar macrophages induced
by IgE triggering or by endotoxin99,100 and increases
the expression of class I and class II MHC molecules
on  macrophages  and  epithelial  cells.  IFN-g is  a
powerful  and  relatively  specific  inhibitor  of  IL-
4-induced IgE and IgG4 synthesis by B-cells.
IFN-g increases  the  production  of  IL-1,  PAF  and
H2O2 from monocytes, in addition to down-regulat-
ing IL-2-induced IL-8 mRNA expression.101–103 IFN-g
also  synergises the effects  of TNF-a in  the  produc-
tion of RANTES from airway smooth muscle cells.65
On  the other hand, IFN-g inhibits  IL-10  production
from  monocytes,104 which  in  turn  leads to  an  up-
regulation  of  TNF-a transcription.105 Thus,  IFN-g
promotes  cell-mediated  cytotoxic  responses,  while
inhibiting  allergic  inflammation  and  IgE  synthesis.
IFN-g up-regulates class II molecules on monocytes/
macrophages  and  dendritic  cells,  and  induces
de  novo expression  on  epithelial,  endothelial  and
other  cells,  thus  making  them  capable  of  antigen
presentation.
Role in allergy and asthma.
There  is  reduced production  of  IFN-g by T-cells  of
asthmatic  patients  and  this  correlates  with  disease
severity.106,107 No polymorphism  of  the IFN-g gene
has been associated with asthma.108Administration of
exogenous IFN-g prevents the airway eosinophilia and
hyper-responsiveness following allergen exposure in
mice.109,110 Liposome-mediated gene transfer of IFN-g
to  the  pulmonary  epithelium  in  sensitised  mice
before secondary antigen exposure also inhibited the
pulmonary  allergic  response.111 IFN-g receptor
knock-out mice develop a prolonged airway eosino-
philia  in  response  to  allergen.112 IFN-g inhibits
allergic  eosinophilia109,113 and airway hyper-respon-
siveness, probably by inducing the formation of IL-10.
These  studies  indicate  that  IFN-g has  a  potential
modulating effect on allergen responses. The inhibi-
tion of the effects of allergen-specific TH2 cells, such
as  eosinophilia,  mucus  goblet  cell  hyperplasia  and
bronchial  hyper-responsiveness,  by  allergen-specific
TH1 cells is mediated by IFN-g .11,12 Allergen immuno-
therapy  of  asthmatic  patients  results  in  increased
production of IFN-g by circulating T-cells114 and in an
increase  in  IFN-g producing  T-cells  in  nasal  biop-
sies.115 Corticosteroid treatment also increases IFN-g
expression in asthmatic airways,116 but in corticoste-
roid-resistant  patients  IFN-g is  unexpectedly
reduced.117 In  asthmatic  patients,  nebulised  IFN-g
reduces the number of eosinophils in bronchoalveo-
lar  lavage,  indicating  its  therapeutic  potential  in
asthma.118
Interleukin-12
Synthesis and release.
IL-12 was initially recognised as a cytokine capable of
synergising  with  IL-2  to  increase  cytotoxic
T-lymphocyte  responses,  and  also  as  an  inducer  of
IFN-g synthesis  by  resting  human  peripheral  blood
mononuclear  cells  in  vitro.  IL-12  is  secreted  by
antigen-presenting  cells,  including  B  lymphocytes,
monocytes/macrophages and dendritic cells.119,120 IL-
12  mRNA  has  been  localised  to  eosinophils  in
bronchoalveolar  lavage  fluid  and  in  peripheral
blood.121
Receptors and signalling.
The IL-12 receptor is composed of two subunits (b 1
and  b 2),which  are  members  of  the  haemopoietin
receptor  superfamily  with  strong  homology  to  the
gp130  receptor.122 The  b 1  receptor  is  not  able  to
transduce  an  IL-12-mediated  signal,  while  the  b 2
subunit when co-expressed with the b 1 subunit forms
a  high-affinity  receptor  for  IL-12  and  results  in
signalling.123 IL-12R  b 2  expression  is  differentially
regulated in TH1 as opposed to TH2 cells,124 while TH1
cells but not TH2 cells express the b 2 subunit.125 On
binding of IL-12 to IL-12R, activation of JAK kinases
occurs, leading to phosphorylation of the receptor,
which become binding sites for STATs that are rapidly
recruited  to  the  receptor  and  tyrosine-phosphory-
lated  by  JAK  kinases. Tyrosine  phosphorylation  of
STAT  proteins induces their dimerisation and trans-
location to the nucleus where they bind to specific
sequences and regulate  transcription. IL-12  stimula-
tion  causes TYK2  and  JAK2  phosphorylation,  and
interaction  of  TYK2  with  IL-12R  b 1  subunit  and
interaction of JAK2 with the IL-12R b 1 subunit.126,127
In TH1 cells and NK cells, IL-12 induces STAT4 to be
tyrosine phosphorylated and activated.126,128 STAT1,
STAT3  and  STAT5  can  also  be  activated  by  IL-
12.128,129
Effects.
IL-12 enhances the growth of activated T-cells and NK
cells130–133 and  enhances  cytotoxic T-cell  and  NK
activity.130,134,135 IL-12 stimulates NK cells and T-cells
to  produce  IFN-g ,  134,136–138 promotes  in  vitro
differentiation  of  mouse  and  human  T-cells  that
secrete IFN-g and TNF-a ,132,136,139,140 and inhibits the
differentiation of T cells into IL-4 secreting cells.139,140
IL-12 indirectly inhibits IL-4-induced human IgE res-
ponses by IFN-g -dependent and -independent mecha-
nisms in vitro.141 Thus, IL-12 can primarily regulate
TH1 cell differentiation, while suppressing the expan-
sion  of  TH2 cell  clones,139 by  early  priming  of
undifferentiated  TH cells  for  IFN-g secretion.142
Together  with  IL-18,  IL-12  induces  anti-CD40  acti-
vated B cells to produce IFN-g , which inhibits  IL-4
dependent IgE production.143 Thus, IL-12 may direct
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intracellular pathogens, whilst inhibiting the develop-
ment  of TH2-like responses and  IgE  synthesis.  IL-12
may  also regulate  airway eosinophilia.144 IL-12  may
play an important role in inhibiting inappropriate IgE
synthesis  and  allergic  inflammation  as  a  result  of
allergen exposure.
Role in allergy and asthma.
A decreased number of IL-12 mRNA positive cells in
airway mucosal biopsies from patients with asthma
has been reported.145 Corticosteroid treatment led to
a reduction in the number of IL-12 mRNA expressing
cells in steroid-sensitive asthmatics, but had no effect
in  steroid-resistant  asthmatics.145 IL-12  production
from whole blood cultures from patients with allergic
asthma was reduced when compared to those from
nonatopic control subjects, together with a reduction
in IL-12-dependent IFN-g production.146 Similarly, the
percentage  of  peripheral  blood  eosinophils  from
asthmatic subjects expressing IL-12 mRNA was lower
compared to nonatopic controls.121
IL-12  may  play  an  important  role  in  inhibiting
inappropriate IgE synthesis and allergic inflammation
as a result of allergen exposure. Thus, IL-12 treatment
of mice during active sensitisation reduced antigen-
induced  influx  of  eosinophils  in  bronchoalveolar
lavage  fluid,  inhibited  IgE  synthesis,  and  abolished
antigen-induced  bronchial  hyperresponsiveness.147
Once an inflammatory response is established, IL-12
inhibits  antigen-induced  bronchial  hyperresponsive-
ness and inflammation.148 These effects of IL-12 are
largely  mediated by  IFN-g .149 In mice, IL-12  admin-
istered at the time of allergic sensitisation decreased
specific  IgE,  tracheal ring  responsiveness to  acetyl-
choline  and  eosinophilia  in  bronchoalveolar lavage
fluid after allergen challenge, together with IL-5 and
IL-10 down-regulation; IL-12 administered after sensi-
tisation  did  not  alter  specific  IgE  levels,  had  little
effect  on  tracheal  ring  responsiveness  and  only  a
modest effect on the recruitment of eosinophils.150
Similarly, in a murine model of house dust mite (Der
p  1)  sensitisation,  IL-12  during  the  sensitisation
period increased Der p 1-specific serum IgG2a while
decreasing  the  levels  of  IgG1  and  IgE  antibodies
following multiple allergen challenges, together with
downregulation of IL-5 production, without affecting
eosinophilia; IL-12 administration after active sensiti-
sation down-regulated IL-5 production, increased IFN-
g production, and abolished recruitment of eosino-
phils.151 Thus, the effect of IL-12 was dependent on
the timing of its administration in relation to active
sensitisation.
Mucosal  gene  transfer  of  IL-12  to  the  lungs  pre-
vented the development of allergic sensitisation and
airways  hyper-responsiveness  dependent  on  IFN-g
expression  and  suppressed  established  allergic  dis-
ease, and reversed the suppression of local antiviral
cell  mediated immunity  responses to vaccinia virus
resulting  in  rapid  resolution  of  virus  infection.152
Similarly, concurrent expression of IL-12 and GM-CSF
in the airway led to inhibition of GM-CSF enhance-
ment  of  ovalbumin-induced  effects  in  the  mouse,
namely  ovalbumin-specific IgE synthesis and airway
eosinophilia, partly due to the expression of IFN-g .153
In another study, the suppressive effect of IL-12 on
antigen-specific TH2-like  cell  development,  IgE  up-
regulation,  airway  hyperresponsiveness  and  eosino-
philia in bronchoalveolar lavage fluid in an allergen-
sensitised  mouse  model  was  only  observed  in
combination  with  IL-18.154 In  mild  allergic  atopic
asthmatics,  IL-12  caused  a  reduction  in  allergen-
induced blood eosinophilia, but did inhibit allergen-
induced late phase responses.
The production of IL-12 and of IL-12-induced IFN-g
release  is  reduced  in  whole  blood  cultures  from
patients  with  allergic  asthma  compared  to  normal
subjects.155 There  is  a  reduction  of  IL-12  mRNA
expression in airway biopsies of patients with allergic
asthma compared to normal subjects, but following
oral  corticosteroid  treatment,  the  levels  of  IL-12
mRNA increased in  corticosteroid-sensitive asthmat-
ics, while  no significant  changes  were observed in
corticosteroid-resistant asthmatics.145 This  contrasts
with the inhibitory effects of corticosteroids on IL-12
production in human monocytes in vitro.156 Allergen
immunotherapy results in an increase in IL-12 expres-
sion.34 PGE2,  b 2-agonists and corticosteroids inhibit
IL-12 production from monocytes.156–158
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